These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 11953332)

  • 41. Budesonide: teaching an old dog new tricks for inflammatory bowel disease treatment.
    Angelucci E; Malesci A; Danese S
    Curr Med Chem; 2008; 15(24):2527-35. PubMed ID: 18855676
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Medical management of specific clinical presentations.
    Bitton A; Peppercorn MA
    Gastroenterol Clin North Am; 1995 Sep; 24(3):541-58. PubMed ID: 8809235
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease.
    Klotz U; Maier K; Fischer C; Heinkel K
    N Engl J Med; 1980 Dec; 303(26):1499-502. PubMed ID: 6107853
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Randomized controlled trials in maintenance of remission in Crohn's disease.
    D'Incà R; Caccaro R
    Rev Recent Clin Trials; 2012 Nov; 7(4):270-83. PubMed ID: 23092231
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Low bioavailability steroids in inflammatory bowel disease: an old chestnut or a whole new ballgame?
    Saibeni S; Meucci G; Papi C; Manes G; Fascì-Spurio F
    Expert Rev Gastroenterol Hepatol; 2014 Nov; 8(8):949-62. PubMed ID: 24882015
    [TBL] [Abstract][Full Text] [Related]  

  • 46. II. Medical treatment of inflammatory bowel disease.
    Gray GM
    Calif Med; 1973 Nov; 119(5):21-4. PubMed ID: 4148269
    [No Abstract]   [Full Text] [Related]  

  • 47. Therapeutical experiments in ulcerative colitis and Crohn's disease.
    Nagy G; Prónay G; Ujszászy L
    Acta Med Hung; 1985; 42(3-4):163-74. PubMed ID: 2869469
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Chronic inflammatory bowel disease: Crohn's disease and ulcerative colitis].
    Fiasse R; Denis MA; Dewit O
    J Pharm Belg; 2010 Mar; (1):1-9. PubMed ID: 20432590
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Budesonide in inflammatory bowel disease.
    Lamers CB; Wagtmans MJ; van der Sluys Veer A; van Hogezand RA; Griffioen G
    Neth J Med; 1996 Feb; 48(2):60-3. PubMed ID: 8819801
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Chronic inflammatory bowel diseases: drug therapy standards and trends].
    Schölmerich J; Stange EF
    Internist (Berl); 2001 Apr; 42(4):533-8, 540-3. PubMed ID: 11326736
    [No Abstract]   [Full Text] [Related]  

  • 51. The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease.
    Bonapace CR; Mays DA
    Ann Pharmacother; 1997; 31(7-8):907-13. PubMed ID: 9220055
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Medical therapy for inflammatory bowel disease.
    Stein RB; Hanauer SB
    Gastroenterol Clin North Am; 1999 Jun; 28(2):297-321. PubMed ID: 10372270
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Budesonide for induction of remission in Crohn's disease.
    Otley A; Steinhart AH
    Cochrane Database Syst Rev; 2005 Oct; (4):CD000296. PubMed ID: 16235274
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oral pH-modified release budesonide for treatment of inflammatory bowel disease, collagenous and lymphocytic colitis.
    Gross V
    Expert Opin Pharmacother; 2008 May; 9(7):1257-65. PubMed ID: 18422482
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Therapeutic principles for chronic inflammatory bowel disease].
    Binder V; Munkholm P
    Ugeskr Laeger; 2001 Jan; 163(1):16-21. PubMed ID: 11586666
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.
    Hanauer SB; Stathopoulos G
    Drug Saf; 1991; 6(3):192-219. PubMed ID: 1676590
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The treatment of inflammatory bowel disease in children.
    Wyllie R; Sarigol S
    Clin Pediatr (Phila); 1998 Jul; 37(7):421-5. PubMed ID: 9675435
    [No Abstract]   [Full Text] [Related]  

  • 58. Budesonide multi-matrix system formulation for treating ulcerative colitis.
    Prantera C; Scribano ML
    Expert Opin Pharmacother; 2014 Apr; 15(6):741-3. PubMed ID: 24484392
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Drug insight: aminosalicylates for the treatment of IBD.
    Nielsen OH; Munck LK
    Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Reccomendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of methotrexate in inflammatory bowel disease].
    Gomollón F; Rubio S; Charro M; García-López S; Muñoz F; Gisbert JP; Domènech E;
    Gastroenterol Hepatol; 2015 Jan; 38(1):24-30. PubMed ID: 25454602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.